Published in Biochem Biophys Res Commun on December 04, 2009
Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature (2011) 4.04
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev (2010) 3.02
A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum Gene Ther (2013) 1.17
The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy. Dis Model Mech (2011) 1.15
Assays for the identification and prioritization of drug candidates for spinal muscular atrophy. Assay Drug Dev Technol (2014) 1.13
The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet (2013) 1.09
Splicing regulation of the survival motor neuron genes and implications for treatment of spinal muscular atrophy. Front Biosci (Landmark Ed) (2010) 0.96
Spinal muscular atrophy: an update on therapeutic progress. Biochim Biophys Acta (2013) 0.93
Characterization of a commonly used mouse model of SMA reveals increased seizure susceptibility and heightened fear response in FVB/N mice. Neurobiol Dis (2011) 0.89
Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci U S A (2016) 0.86
Antisense oligonucleotide mediated therapy of spinal muscular atrophy. Transl Neurosci (2013) 0.85
TSUNAMI: an antisense method to phenocopy splicing-associated diseases in animals. Genes Dev (2012) 0.84
A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol Ther Nucleic Acids (2014) 0.84
RNA-sequencing of a mouse-model of spinal muscular atrophy reveals tissue-wide changes in splicing of U12-dependent introns. Nucleic Acids Res (2016) 0.80
Autophagy dysregulation in cell culture and animals models of spinal muscular atrophy. Mol Cell Neurosci (2014) 0.80
Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy. Nucleic Acid Ther (2017) 0.77
Characterization of a large human transgene following invasin-mediated delivery in a bacterial artificial chromosome. Chromosoma (2013) 0.76
Altered mRNA Splicing in SMN-Depleted Motor Neuron-Like Cells. PLoS One (2016) 0.75
DNA Damage Response and DNA Repair in Skeletal Myocytes From a Mouse Model of Spinal Muscular Atrophy. J Neuropathol Exp Neurol (2016) 0.75
Identification and characterization of a spinal muscular atrophy-determining gene. Cell (1995) 17.41
A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A (1999) 7.60
The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet (2000) 5.38
SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet (2005) 5.23
The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet (1997) 4.86
Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A (1997) 4.70
A mouse model for spinal muscular atrophy. Nat Genet (2000) 4.37
The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis (1996) 3.71
Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest (2007) 3.11
Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy. Hum Mol Genet (2000) 2.09
A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy. J Cell Biol (2003) 1.75
Cloning, characterization, and copy number of the murine survival motor neuron gene: homolog of the spinal muscular atrophy-determining gene. Genome Res (1997) 1.59
Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med (Berl) (2008) 1.38
Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. Hum Mol Genet (2009) 1.30
Regular exercise prolongs survival in a type 2 spinal muscular atrophy model mouse. J Neurosci (2005) 1.17
Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol Dis (2006) 1.11
Exercise-induced activation of NMDA receptor promotes motor unit development and survival in a type 2 spinal muscular atrophy model mouse. J Neurosci (2008) 1.06
Restoring Bcl-x(L) levels benefits a mouse model of spinal muscular atrophy. Neurobiol Dis (2008) 0.97
Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet (2008) 2.82
Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum Mol Genet (2010) 1.75
Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mamm Genome (2011) 1.47
Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. J Neurosci (2012) 1.42
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids (2012) 1.41
A SMN missense mutation complements SMN2 restoring snRNPs and rescuing SMA mice. Hum Mol Genet (2009) 1.31
Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Hum Mol Genet (2009) 1.09
Multiple isoforms of the KC1 cotransporter are expressed in sickle and normal erythroid cells. Exp Hematol (2005) 0.99
PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res (2011) 0.97
Characterization of behavioral and neuromuscular junction phenotypes in a novel allelic series of SMA mouse models. Hum Mol Genet (2012) 0.96
Development of electrocardiogram intervals during growth of FVB/N neonate mice. BMC Physiol (2010) 0.94
Discovery of transgene insertion sites by high throughput sequencing of mate pair libraries. BMC Genomics (2014) 0.90
Characterization of a commonly used mouse model of SMA reveals increased seizure susceptibility and heightened fear response in FVB/N mice. Neurobiol Dis (2011) 0.89
Antisense oligonucleotide mediated therapy of spinal muscular atrophy. Transl Neurosci (2013) 0.85
Use of cell-penetrating-peptides in oligonucleotide splice switching therapy. Curr Gene Ther (2012) 0.84
Optimizing tissue-specific antisense oligonucleotide-peptide conjugates. Methods Mol Biol (2012) 0.79
Design and application of bispecific splice-switching oligonucleotides. Nucleic Acid Ther (2014) 0.77
Restoration of SMN to Emx-1 expressing cortical neurons is not sufficient to provide benefit to a severe mouse model of Spinal Muscular Atrophy. Transgenic Res (2013) 0.76
Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides. Nucleic Acid Ther (2015) 0.75